Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 3 institutions in 2 countries.
Kristopher R GenschmerDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-1836-9522
Cintia F M VadesilhoLaboratório de Bacteriologia, Instituto Butantan, Sao Paulo, Sao Paulo, Brazil.
Larry S McDanielDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, Mississippi, USA.ORCID 0000-0002-1649-7563
Sang-Sang ParkDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Yvette HaleDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Eliane N MiyajiLaboratório de Bacteriologia, Instituto Butantan, Sao Paulo, Sao Paulo, Brazil.
David E BrilesDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA dbriles@uab.edu.
University of Alabama at Birmingham · USInstituto Butantan · BRUniversity of Mississippi Medical Center · US
Funding
PspA: A Potential Pneumococcal Vaccine ComponentR01AI021548 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BRILES, DAVID E · 1985 to 2012
$6.0M
Effect of the Middle Ear Inflammation On the Inner EarR01DC006452 · NIDCD · UNIVERSITY OF MINNESOTA · PI BRILES, DAVID E, FERRIERI, PATRICIA · 2006 to 2014
$2.4M
Vaccine potential of the proline-rich domain of pneumococcal surface protein AR01AI118805 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BRILES, DAVID E · 2015 to 2019
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA. · full record | OpenQuestion